dendriitrakkvaktsiine

Dendriitrakkvaktsiine, also known as dendritic cell vaccines, are a type of cancer immunotherapy that aims to stimulate the patient's immune system to recognize and attack cancer cells. This approach leverages the unique role of dendritic cells, which are professional antigen-presenting cells, in initiating and orchestrating immune responses.

The process typically involves isolating dendritic cells from a patient's blood. These cells are then cultured and exposed to tumor-associated antigens, which are specific proteins found on the surface of cancer cells. This "education" process primes the dendritic cells to effectively present these antigens to other immune cells, particularly T cells.

Once loaded with tumor antigens, the activated dendritic cells are re-infused back into the patient. Their role is to migrate to lymph nodes and present the tumor antigens to T cells, thereby activating them. These activated T cells then proliferate and seek out and destroy cancer cells expressing the same antigens.

Dendriitrakkvaktsiine are considered personalized therapies because they are often derived from the patient's own cells and targeted against their specific tumor antigens. Research and clinical trials have explored their use in various cancers, including prostate cancer, melanoma, and glioblastoma, with ongoing efforts to improve their efficacy and broaden their application.